US FDA Pushing Coronavirus Trial Sponsors To Include Control Groups
Executive Summary
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”
You may also be interested in...
For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
EU Regulators Concerned By Mushrooming Of Small COVID-19 Trials
Based on experience from earlier epidemics, EU regulators are concerned that the high number of COVID-19 trials starting in a confined geography at the peak of the coronavirus pandemic will not be able to enrol patients up to their pre-established sample size.
US FDA Welcomes Variety Of Phase II/III Trial Designs For COVID-19 Therapies, But With Standards
Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.